Joris van Dongen

267 Facial lipografting on skin quality: a systematic review Table 7. Statement for designing a proper and well-designed clinical trial for facial lipofilling. Study design Patient demographics Treatment Outcomes • Placebo vs. treatment or • Treatment vs. treatment • Lipofilling without other treatments* • Randomized • Double-blinded** • Follow-up with a minimum of 1 year Inclusion criteria • ASA1 with a BMI <30 for at least 1 year • Non-smokers: >1-year non-smoking • Uniform population of females or males • Age: minimum of 35 Exclusion criteria • Diabetes mellitus type 1 or type 2 • Human immunodeficiency virus • Immunological diseases • Collagen diseases • Interventions of the face 1 year prior to the date of surgery • Active child wish • Active use of hormone replacement therapy∞ • History of a psychiatric disorder • Standardized harvesting location • Centrifuged adipose tissue as • described by Coleman • Well documented injection volumes per deep, superficial and intradermal anatomical locationº • Number of sessions need to be standardized • Maximum time of 30 min. between lipoharvesting and injection Primary outcome • Skin elasticity measured with the cutometer Secondary outcome • Patient satisfaction measured with the FACE-Q • Clinical photographs analysed by a blinded and independent observer • Number of complications *Lipofiling can only be combined with cSVF, tSVF or PRP-like treatments. ** Patient as well as investigator performing measurements preoperative and during follow-up. ∞ Hormonal birth control treatments are excluded. ºTemporal, nasojugal groove, central midface, nasolabial fold, marionette-line/prejowling/chin. ASA = American Society of Anaesthesiology